HCM · available-data snapshot
HUTCHMED (China) Limited (HCM): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for HUTCHMED (China) Limited (HCM); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for HCM?
We do not publish a fair value for HUTCHMED (China) Limited. What we can say from its filings and market data is below.
What is HCM's TickerWorth Score?
Priced richly vs peers — the business scores well
Compared with Healthcare companies in US
Its strongest point: strong balance sheet. Its weakest: profitability is weak.
- Value · 39 of 100
Cheaper than 39% of Healthcare companies in US
- Price vs worth · 28 of 100
- Quality · 29 of 100
More profitable than 29% of Healthcare companies in US
- Financial health · 90 of 100
Financially stronger than 90% of Healthcare companies in US
- Growth · 39 of 100
Growing faster than 39% of Healthcare companies in US
- Momentum · 62 of 100
Outperformed 62% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $14.14
- Market cap
- $2,
457, 732, 608 - 52-week high
- $16.33
- 52-week low
- $9.77
- Currency
- USD
- Exchange
- NasdaqGS
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for HUTCHMED (China) Limited (HCM) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, HCM trades at a recent price of $14.14, a market capitalisation of about $2,457,732,608, sitting 67% of the way up its 52-week range ($9.77–$16.33), on the NasdaqGS.
The standard alternative to a DCF is relative valuation — comparing HCM's trading multiples against a sector benchmark. Here that gives P/E of 141.4× (richer than the peer median of 42.2×); Fwd P/E of 54.6× (richer than the peer median of 17.6×); P/B of 1.9× (cheaper than the peer median of 7.9×); P/S of 4.5× (cheaper than the peer median of 6.2×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. HCM shows a price-to-book (P/B) of 1.95 and book value of $7.25 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. HCM is in an up-trend (price above both its 50- and 200-day averages), trading -13.4% from its 52-week high. Over the past year the stock is -7.0%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
HCM vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | HCM | Peer median | Read |
|---|---|---|---|
| P/E | 141.4× | 42.2× | richer than |
| Fwd P/E | 54.6× | 17.6× | richer than |
| P/B | 1.9× | 7.9× | cheaper than |
| P/S | 4.5× | 6.2× | cheaper than |
What does HUTCHMED (China) Limited do?
What does it do?
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It operates in the Drug Manufacturers - Specialty & Generic industry (Healthcare sector), headquartered in Hong Kong. The company employs roughly 1,790 people.
How does it make money?
The business turns $549M in annual revenue into profit. Out of every $100 of sales, about $0 is left as operating profit (operating margin of 0.3%), after a 13% gross margin on the products/services it sells. After all costs, taxes and interest, 3.3% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries modest debt (0.1× equity), comfortably covers its short-term bills (5.6× current ratio), and is currently profitable.
HCM insider trading
We have no recent SEC Form 4 insider filings on file for HUTCHMED (China) Limited. Form 4 covers US-listed companies only.
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.